Availability, Timeliness of Availability of New Cancer Drugs Vary
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 10, 2024 -- Across countries, there are considerable disparities in the availability and timeliness of availability of new cancer drugs, according to a study published online Oct. 8 in BMJ Global Health.
Meng Li, Ph.D., from Tufts Medical Center in Boston, and colleagues examined the availability and timeliness of availability of new cancer drugs between 1990 and 2022. The number of new drugs launched in each country and delay in launches were calculated.
The researchers identified 568 cancer drugs that were launched for the first time globally between 1990 and 2022. Of these, 35, 22, 15, and 28 percent were launched in only one country, in two to five countries, in six to 10 countries, and in more than 10 countries by 2022, respectively. During this period, the number of new drugs launched in a country ranged from 0 to 345. From the first global launch to the second, third, fourth, and fifth launch, the average delays were 18.0, 24.3, 32.5, and 39.4 months, respectively. More launches and shorter delays were seen in association with higher Gross National Income per capita and cancer incidence, respectively.
"Despite considerable progress in the discovery and development of new cancer medicines in recent decades, many of these medicines remained unavailable many years after their first global launch or were only available after long delays," the authors write. "This disparity underscores the need for policy solutions to provide more equitable access to cancer medicines globally."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-11 06:00
Read more
- Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
- Nearly 260 Million Americans Could Be Overweight or Obese by 2050
- ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
- ASN: 1990 to 2021 Saw Global Rise in Chronic Kidney Disease Cases, Deaths in Women
- Sleep Apnea Increases Risk for Dementia in Older Adults Over Time
- Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions